Literature DB >> 29621376

Management of Metastatic Melanoma in 2018.

Howard L Kaufman1, Kim Margolin2, Ryan Sullivan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29621376     DOI： 10.1001/jamaoncol.2018.0170

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

Review 1.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

2.  Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.

Authors:  Jean-François Baurain; Caroline Robert; Laurent Mortier; Bart Neyns; Florent Grange; Céleste Lebbe; Fernando Ulloa-Montoya; Pedro Miguel De Sousa Alves; Marc Gillet; Jamila Louahed; Silvija Jarnjak; Frédéric F Lehmann
Journal:  ESMO Open       Date:  2018-07-25

3.  17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes.

Authors:  Aleksandra Mielczarek-Lewandowska; Malgorzata Sztiller-Sikorska; Marta Osrodek; Malgorzata Czyz; Mariusz L Hartman
Journal:  Apoptosis       Date:  2019-08       Impact factor: 4.677

Review 4.  Fibroblast Growth Factor Receptor Signaling in Skin Cancers.

Authors:  Malgorzata Czyz
Journal:  Cells       Date:  2019-06-04       Impact factor: 6.600

5.  Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.

Authors:  Xinan Sheng; Xieqiao Yan; Zhihong Chi; Lu Si; Chuanliang Cui; Bixia Tang; Siming Li; Lili Mao; Bin Lian; Xuan Wang; Xue Bai; Li Zhou; Yan Kong; Jie Dai; Kai Wang; Xiongwen Tang; Huaning Zhou; Hai Wu; Hui Feng; Sheng Yao; Keith T Flaherty; Jun Guo
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

6.  Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: A population-based study.

Authors:  Pragya Rai; Chan Shen; Joanna Kolodney; Kimberly M Kelly; Virginia G Scott; Usha Sambamoorthi
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

Review 7.  The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.

Authors:  Biao Ning; Yixin Liu; Miao Wang; Yi Li; Tianzi Xu; Yongchang Wei
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

8.  Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma.

Authors:  Pragya Rai; Chan Shen; Joanna Kolodney; Kimberly M Kelly; Virginia G Scott; Usha Sambamoorthi
Journal:  Immunotherapy       Date:  2020-11-05       Impact factor: 4.196

Review 9.  Inhibitors of HSP90 in melanoma.

Authors:  Aleksandra Mielczarek-Lewandowska; Mariusz L Hartman; Malgorzata Czyz
Journal:  Apoptosis       Date:  2020-02       Impact factor: 4.677

10.  Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

Authors:  Anna Stagno; Sabrina Vari; Alessio Annovazzi; Vincenzo Anelli; Michelangelo Russillo; Francesco Cognetti; Virginia Ferraresi
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.